Fiber pills may ease radiation side effects for pelvic cancer patients
NCT ID NCT04534075
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 2 times
Summary
This completed phase 3 trial tested whether taking psyllium husk fiber capsules during pelvic radiation therapy could reduce gut inflammation and urgency symptoms. 354 adults with pelvic cancers (like rectal, prostate, or gynecological) took either fiber or placebo capsules daily. The study measured blood inflammation markers and patient-reported bowel urgency to see if extra fiber helps long-term gut health.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dietary fiber from psyllium husk
What this could lead to
If it works, this could offer a simple, low-cost way to protect the gut and reduce urgent bowel symptoms during pelvic radiation therapy.
What could go wrong
This is a completed phase 3 trial, but the added fiber might increase acute side effects instead of helping. Results are not yet published, so we don't know if it worked.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Jubileumskliniken, Sahlgrenska University Hospital
Gothenburg, 413 45, Sweden